Organogenesis Inc is launching its new PuraPly™ wound-management products at the American Podiatric Medical Association Annual Scientific Meeting (APMA) in Orlando, Fla.
This includes the PuraPly Antimicrobial (PuraPly AM), the first Food and Drug Administration (FDA)-cleared purified collagen matrix with polyhexamethylene biguanide hydrochloride (PHMB) antimicrobial agent.
PuraPly and PuraPly AM are the latest additions to the Organogenesis portfolio of advanced wound care products. Both products are FDA 510(k)-cleared Class II medical devices approved for acute and chronic wound management across a variety of wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, and venous and diabetic ulcers.
When used within the first 4 weeks of treatment, PuraPly creates an optimal environment for wounds of varying depth, regardless of severity or duration. PuraPly comprises layers of inherently strong, purified, and biocompatible natural collagen matrix. PuraPly AM combines purified collagen with PHMB, which provides broad antimicrobial coverage, protecting against a wide range of bacteria that colonize wounds, and can progress to biofilm formation and infection. PuraPly AM can reduce the bacterial load in the wound bed, which, if not addressed, can negatively impact tissue repair and delay healing. PuraPly AM and PuraPly are both available in a range of sizes, in order to meet the needs of a variety of wound types.
Both PuraPly and PuraPly AM have been approved for pass-through reimbursement in the hospital outpatient setting by the Centers for Medicare and Medicaid Services.
For diabetic ulcer and venous leg ulcer wounds that are truly chronic and do not respond to wound management, Organogenesis offers Apligraf and Dermagraft bioengineered living cell-based products, the only FDA-approved wound-healing therapies in the “skin substitute” class.”